CoDiagnostics Implements 1-for-30 Reverse Stock Split for Nasdaq Compliance

CoDiagnostics Implements Reverse Stock Split to Ensure Nasdaq Compliance

CoDiagnostics, Inc., a Utah-based molecular diagnostics company, announces a strategic move to implement a reverse stock split at a ratio of 1-for-30, effective January 2, 2026. This decision comes after stockholders approved the split at a Special Meeting held on December 5, 2025, where they voted on various potential split ratios. The primary objective of this action is to help the company meet the $1.00 minimum bid price requirement essential for maintaining its listing on The Nasdaq Capital Market. By consolidating shares, Co-Diagnostics aims to enhance its market position and streamline its stock structure.

The reverse stock split will automatically combine every 30 shares of Co-Diagnostics' common stock into one validly issued share, without altering the par value of the shares. This consolidation not only addresses compliance issues but also adjusts the number of shares available under the company's equity incentive plans. Consequently, this will result in modifications to the number of shares that can be issued upon the exercise of stock options and warrants, along with a proportional increase in the exercise prices. Importantly, the company assures that no fractional shares will be issued as a result of this split; any entitlements to fractional shares will be rounded up to the next whole share, providing clarity and simplicity for shareholders.

As Co-Diagnostics prepares for the split, trading will continue under the ticker symbol "CODX" on a split-adjusted basis beginning January 2, 2026. The company encourages stockholders to consult the definitive proxy statement filed with the Securities and Exchange Commission for further details regarding the reverse stock split. For inquiries, shareholders holding shares in brokerage accounts are advised to contact their brokers, while others can reach out to the company's transfer agent, VStock Transfer, LLC. This move is part of Co-Diagnostics' broader strategy to strengthen its financial standing and ensure compliance with market regulations, allowing the company to focus on its core mission in the molecular diagnostics field.

In addition to the reverse stock split, Co-Diagnostics continues to enhance its portfolio of molecular diagnostic testing solutions. The company specializes in developing innovative technologies for detecting various diseases, including infectious diseases and genetic disorders, a critical area in healthcare. As the demand for reliable diagnostic testing grows, Co-Diagnostics remains committed to advancing its offerings to meet the needs of healthcare providers and patients alike.